Hey that is excess mortality in the treatment arm. That is not good. A hold because of an adverse event is one thing, but this is a hold because treated patients are doing worse than controls.. What are the chances of ever re-starting a trial with that outcome???
So is there anyone who would trust this company to not cherry pick the IP intervention patients? Oh yeah, look how great these kids are doing BEFORE they were treated. Bear in mind that this is a disease with widely variable penetrance..